EUCTR2013-002343-29-GB进行中（未招募）不适用
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia - ODYSSEY CHOICE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 803
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Men and women > age 18 or legal age of majority with elevated LDL-C.
- •2. Patients not having adequate control of their hypercholesterolemia, defined as follows: for moderate and high CVD risk, LDL-C =100 mg/dL, and for very high CVD risk, LDL-C = 70 mg/dL. Patients who are not on statin therapy must be at moderate CVD risk and must have LDL-C <160 mg/dL (<4.14 mmol/L). Patients who are statin intolerant may be at moderate CVD risk or greater. Patients who are statin intolerant must have LDL-C <160 mg/dL (<4.14 mmol/L), if they are not receiving any other non-statin LMT. There is no upper limit for LDL-C for patients who are statin intolerant and are receiving clinically appropriate
- •lipid-lowering therapy (as they are already on standard of care). See protocol for CVD risk categories and definition of statin intolerance.
- •3. If on statin therapy, patients on the following medications/doses for at least 28 days prior to the screening visit are allowed: atorvastatin 40 mg or 80 mg, rosuvastatin 20 mg or 40 mg, or simvastatin 80 mg (must be on stable dose of simvastatin for at least 1 year), or their maximally tolerated dose of 1 of these 3 statins.
- •4. Willing and able to comply with clinic visits and study-related procedures.
- •5. Provide signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 525
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 175
排除标准
- •1. Patient with homozygous FH (clinically or by previous genotyping)
- •2. Currently taking a statin that is not atorvastatin, rosuvastatin, or simvastatin
- •3. Use of fibrates other than fenofibrate within 6 weeks of the screening visit
- •4. Use of allowed LMTs (eg, omega-3 fatty acids, cholesterol absorption inhibitors [eg, ezetimibe], bile acid resins, niacin, and plant stanols/sterols [such as those found in Benecol®, flax seed oil, or psyllium]) that have not been at a stable dose/regimen for at least 4 weeks prior to the screening visit
- •5. Use of nutraceutical products or over-the-counter therapies that may affect lipids and that have not been at a stable dose/amount for at least 4 weeks prior to the screening visit
- •6. Use of red yeast rice products within 4 weeks of the screening visit or between screening and randomization visits
- •7. Uncontrolled hypothyroidism
- •8. Uncontrolled blood pressure (systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg) at the screening visit
- •9. Patient who has received plasmapheresis treatment within 2 months prior to the screening visit, or has plans to receive it during the study
- •10. Recent (within 3 months prior to the screening visit) myocardial infarction, unstable angina leading to hospitalization, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), uncontrolled cardiac arrhythmia, stroke, transient ischemic attack, carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease
- •11. Planning to undergo scheduled PCI, CABG, or carotid or peripheral revascularization during the study
- •12. Known history of a hemorrhagic stroke
- •13. History of New York Heart Association Class III or IV heart failure within 12 months prior to the screening visit.
- •14. Newly diagnosed diabetes (within 3 months prior to the screening visit) or poorly controlled diabetes (hemoglobin A1c [HbA1c] >9% at the screening visit)
- •15. History of bariatric surgery within 12 months prior to the screening visit
- •16. Unstable weight, defined by a variation >5 kg within 2 months prior to the screening visit
- •17. Known history of loss of function of PCSK9 (ie, genetic mutation or sequence variation)
- •18. Use of systemic corticosteroids, unless used as replacement therapy for pituitary/adrenal disease with a stable regimen for at least 6 weeks prior to randomization
- •19. Use of continuous estrogen or testosterone hormone replacement therapy, unless the regimen has been stable for 6 weeks prior to the screening visit and there are no plans to change the regimen during the study
- •20. History of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer
- •21. Known history of positive test for human immunodeficiency virus (HIV)
- •22. Has been previously treated with at least 1 dose of alirocumab or any other anti-PCSK9 monoclonal antibody in other clinical studies
- •23. Has taken any active investigational drugs within 1 month or 5 half-lives, whichever is longer; however, patients who have taken anti-PCSK9 therapy at any time are excluded
- •24. Conditions/situations such as:
- •? Any clinically significant abnormality identified at the time of screening that in the judgment of the investigator or any sub-investigator would preclude safe completion of the study or constrain assessment of endpoints, such as major systemic diseases or patients with short life expecta
研究者
相似试验
进行中（未招募）
1 期
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
进行中（未招募）
1 期
A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia (CAH)MedDRA version: 20.0Level: LLTClassification code 10010323Term: Congenital adrenal hyperplasiaSystem Organ Class: 100000004850EUCTR2019-004873-17-DEeurocrine Biosciences, Inc.165
进行中（未招募）
1 期
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placeboEUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078EUCTR2005-006029-94-BEEisai Limited720
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943NL-OMON30044Janssen-Cilag82